The United States Food and Drug Administration (US FDA) has concluded inspection at Aurobindo Pharma’s Unit VI - B, a Formulation manufacturing facility, situated at Sangareddy District, Telangana. US FDA has conducted inspection from September 22 to September 29, 2023. At the end of the inspection, a ‘Form 483’ was issued with 1 observation which is procedural in nature.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.00 |
| Dr. Reddys Lab | 1233.90 |
| Cipla | 1241.30 |
| Zydus Lifesciences | 947.00 |
| Lupin | 2328.30 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: